Evidence map›Paper›PMID 35439048›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome.

Mercedes Tkach, Jessie Thalmensi, Eleonora Timperi, Paul Gueguen, Nathalie Névo, Eleonora Grisard, Philemon Sirven, Federico Cocozza, Alizée Gouronnec, Lorena Martin-Jaular and 9 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The immunology of human breast cancer.Nature reviews. Immunology · 2026
    Review
  3. Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026
    Review
  4. Review
  5. Review
  6. Cancers · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mercedes TkachINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
Jessie ThalmensiINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
Eleonora TimperiINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
Paul GueguenINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0003-2930-6073
Nathalie NévoINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0001-6350-7122
Eleonora GrisardINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0002-4585-9244
Philemon SirvenINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
Federico CocozzaINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0003-4311-3083
Alizée GouronnecINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
Lorena Martin-JaularINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0002-1511-8576
Mabel JouveCNRS UMR3215, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0002-3115-4681
Fabien DelisleINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
Nicolas ManelINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0002-1481-4430
Derek C RookhuizenINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.
Coralie L GuerinCytometry Platform, CurieCoreTech, Institut Curie, Paris, F-75005 France.ORCID 0000-0002-1840-4017
Vassili SoumelisUniversité de Paris, Inserm, U976 HIPI Unit, F-75006, Paris, France.
Emanuela RomanoINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0002-1574-5545
Elodie SeguraINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0003-1795-1921
Clotilde ThéryINSERM U932, Institut Curie, PSL Research University, 75005, Paris, France.ORCID 0000-0001-8294-6884

Funding

Extracellular Vesicle-Mediated Immunomodulation in HIV Infection and Nicotine AbuseR01DA040385 · NIDA · JOHNS HOPKINS UNIVERSITY · PI WITWER, KENNETH W · 2015 to 2019
$2.3M
NIDA NIH HHS R01 DA040385
6 · The paper itself

Abstract

Tumor associated macrophages (TAMs), which differentiate from circulating monocytes, are pervasive across human cancers and comprise heterogeneous populations. The contribution of tumor-derived signals to TAM heterogeneity is not well understood. In particular, tumors release both soluble factors and extracellular vesicles (EVs), whose respective impact on TAM precursors may be different. Here, we show that triple negative breast cancer cells (TNBCs) release EVs and soluble molecules promoting monocyte differentiation toward distinct macrophage fates. EVs specifically promoted proinflammatory macrophages bearing an interferon response signature. The combination in TNBC EVs of surface CSF-1 promoting survival and cargoes promoting cGAS/STING or other activation pathways led to differentiation of this particular macrophage subset. Notably, macrophages expressing the EV-induced signature were found among patients’ TAMs. Furthermore, higher expression of this signature was associated with T cell infiltration and extended patient survival. Together, this data indicates that TNBC-released CSF-1-bearing EVs promote a tumor immune microenvironment associated with a better prognosis in TNBC patients.

Indexed as

Extracellular VesiclesTriple Negative Breast NeoplasmsHumansMacrophagesCSF-1exosomesextracellular vesiclesmacrophagestriple-negative breast cancer

Identifiers

PMID35439048
PMCPMC9169908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.